Hantavirus — Fragen mit Antworten

Im Allgemeinen nein. Die meisten Hantavirus-Spezies — darunter Sin-Nombre-Virus, Puumala, Hantaan und Seoul — werden ausschließlich durch Kontakt mit infizierten Nagetieren oder deren Ausscheidungen, Urin und Speichel übertragen. Die einzige dokumentierte Ausnahme ist das Andes-Virus (ANDV), das vor allem in Argentinien und Chile vorkommt. Für das Andes-Virus wurde eine begrenzte Übertragung von Mensch zu Mensch beschrieben, jedoch nur bei engem, längerem Kontakt (z. B. Haushaltsmitglieder oder medizinisches Personal ohne Schutzausrüstung). Das Cluster an Bord der MV Hondius betrifft das Andes-Virus; aus diesem Grund wird trotz der Seltenheit einer Mensch-zu-Mensch-Übertragung international Kontaktnachverfolgung durchgeführt.

The MV Hondius 2026 cluster is the first documented hantavirus outbreak linked to cruise ship travel, but the ship environment was not itself the source of transmission. Hantavirus does not spread easily from person to person — the source was an index case who had spent four months in Andes virus-endemic areas of Argentina, Chile, and Uruguay before boarding. Andes virus is the only hantavirus strain with documented (but limited) person-to-person transmission, requiring prolonged close contact. WHO and ECDC assessed the risk to the general public from the MV Hondius cluster as 'low' to 'very low'. The episode demonstrates that travelers returning from Andes-endemic South American regions within 8 weeks of symptoms should disclose that travel history to clinicians immediately.

Die Inkubationszeit beim Hantavirus liegt typischerweise zwischen einer und acht Wochen nach Exposition, wobei die meisten Fälle zwei bis vier Wochen nach dem Kontakt Symptome zeigen (CDC). Diese lange Inkubationszeit ist einer der Gründe, warum die WHO Passagiere und Kontakte der MV Hondius weiter aktiv überwacht: Da die Passagiere am 24. April 2026 in Sankt Helena von Bord gegangen sind und sich nun in sechs Ländern aufhalten, könnten neue Fälle, die mit dem Cluster in Verbindung stehen, noch bis Mitte Juni 2026 auftreten.

Ebola is NOT airborne. Human-to-human transmission requires direct contact with the blood or body fluids (saliva, vomit, urine, feces, breast milk, semen) of a symptomatic or deceased infected person, or with surfaces and objects contaminated by those fluids. Traditional burial practices involving contact with the deceased are a well-documented transmission route, as is nosocomial spread in healthcare settings lacking adequate infection control. The virus can also persist in semen for months after recovery, making sexual transmission possible. Animal-to-human spillover is believed to originate from fruit bats (Pteropodidae) and infected non-human primates.

Das Hantavirus wird vor allem von Nagetieren auf den Menschen übertragen, auf vier Hauptwegen: (1) Inhalation aerosolisierter Ausscheidungen (Urin, Kot, Speichel) infizierter Nagetiere — der häufigste Übertragungsweg, vor allem in schlecht belüfteten geschlossenen Räumen wie Hütten, Garagen, Schuppen und Scheunen. (2) Direkter Kontakt mit Nagetieren, deren Ausscheidungen oder kontaminierten Oberflächen, insbesondere über verletzte Haut oder Schleimhäute. (3) Biss durch ein infiziertes Nagetier (selten). (4) Verzehr von mit Nagetierausscheidungen kontaminierten Lebensmitteln. Beim Andes-Virus ist zudem eine seltene Mensch-zu-Mensch-Übertragung dokumentiert, die engen, längeren Kontakt erfordert (z. B. Haushaltsmitglieder, medizinisches Personal ohne Schutzausrüstung). Das Hantavirus wird nicht durch Mücken, Zecken oder andere Gliederfüßer übertragen.

Measles is one of the most contagious infectious diseases known. It spreads through the air via tiny respiratory aerosols and droplets released when an infected person coughs, sneezes, or breathes. The virus can survive in the air and on surfaces for up to 2 hours after an infected person has left a room — meaning you can catch measles without direct contact. The basic reproduction number (R₀) is 12–18: each infectious person can infect 12 to 18 unvaccinated contacts in a susceptible population. An infected person is contagious from about 4 days before their rash appears through 4 days after — roughly 8 days total, often before they know they are sick. Measles has no animal reservoir, which means it can only survive by continuously infecting people. This makes herd immunity — achieved through ≥95% two-dose MMR vaccination — the only sustainable way to stop transmission.

Smallpox spread almost exclusively person-to-person through respiratory droplets and direct contact with skin lesions, and was highly contagious with a basic reproduction number (R0) of 5-7. Mpox is less transmissible: clade IIb (2022 outbreak) spread primarily through close physical and sexual contact, with an estimated R0 of 1.1-2.4 in the MSM community. Mpox also has a zoonotic reservoir (rodents, primates), meaning it can re-enter the human population from animals — unlike smallpox, which had no animal reservoir.

The primary route is contact with the multimammate rat (Mastomys natalensis) — specifically its urine, faeces, or saliva — or by handling and consuming infected rats. Human-to-human transmission occurs through direct contact with blood, urine, faeces, vomit, or other bodily fluids of an infected person. Lassa fever is NOT airborne; casual contact poses minimal risk. Healthcare workers are at risk without adequate PPE. Sexual transmission is documented during convalescence, as the virus persists in semen for up to three months.

Das Hantavirus ist nicht in dem Sinne luftübertragen wie COVID-19 oder Masern. Es wird über Aerosole übertragen, die entstehen, wenn getrocknete Nagetierausscheidungen (Urin, Kot, Speichel) aufgewirbelt und lokal in der Luft verteilt werden — etwa beim Fegen einer mit Nagetieren befallenen Hütte oder beim Saugen trockener Ausscheidungen. Der 'luftgetragene' Anteil der Übertragung ist also kurzreichweitig und an bestimmte Umweltbedingungen gebunden und nicht in gemeinsam genutzten Räumen über die Zeit einatembar, wie es bei klassischen respiratorischen Erregern der Fall ist. Die Ausnahme beim Andes-Virus betrifft engen, längeren Kontakt zwischen Menschen und ist ebenfalls keine klassische respiratorische Tröpfchen- oder Aerosolübertragung. Eine ausreichende Lüftung (mindestens 30 Minuten geöffnete Fenster vor Betreten einer geschlossenen Hütte) senkt das Risiko wirksam.

Lassa fever can spread person-to-person, but is far less contagious than diseases like measles or COVID-19. Transmission requires direct contact with the blood, urine, faeces, vomit, or other bodily fluids of an infected person — casual contact, sharing air, or coughing do not spread the virus. Healthcare workers who treat Lassa patients without adequate PPE are at significant risk. Sexual transmission is documented during convalescence because the virus persists in semen for up to three months. Large household clusters are uncommon; most secondary cases occur in healthcare settings without strict infection control. This is in contrast to Ebola, which has caused much larger nosocomial clusters.

Mpox is not classified as a traditional sexually transmitted infection (STI), but sexual contact is an efficient transmission route. During the 2022 clade IIb global outbreak, the majority of cases in high-income countries involved men who have sex with men (MSM), transmitted through close skin-to-skin contact during sex. The virus spreads via direct contact with lesions, rash, or body fluids — circumstances common during sexual activity. However, mpox also transmits through non-sexual close contact (household, healthcare settings), distinguishing it from classic STIs.

A person with measles is contagious from approximately 4 days before the rash appears through 4 days after rash onset — a total infectious window of about 8 days. This means an infected person is spreading measles before they even know they have it, since the rash does not appear until the disease has been progressing for several days. During the prodromal phase (before the rash), the only symptoms are fever, cough, runny nose, and red eyes — easily mistaken for a common cold or flu. This pre-rash contagiousness is one of the main reasons measles outbreaks are so hard to contain: by the time someone is diagnosed, they may have already exposed many others. People with measles should be isolated from others from 4 days before rash onset through 4 days after rash onset, per CDC guidelines.

Ebola virus disease has a historical case-fatality rate of 25-90% depending on strain, with Bundibugyo ebolavirus — the strain driving the active 2026 outbreak in the Democratic Republic of the Congo and Uganda — historically around 25-40%. Per the WHO Situation Report of 18 May 2026, the outbreak had recorded 528 reported cases (2 lab-confirmed in Uganda, 526 under investigation) and 132 deaths, with 668 contacts identified. No vaccine or monoclonal antibody therapy is currently approved for the Bundibugyo strain, unlike Zaire ebolavirus which has Ervebo and two approved antibody treatments. WHO declared the outbreak a Public Health Emergency of International Concern on 18 May 2026.

Die Sterblichkeit unterscheidet sich stark zwischen den Virusarten. Andes-Virus und Sin-Nombre-Virus, die Erreger des Hantavirus-Lungensyndroms (HPS), weisen eine Letalitätsrate (CFR) von 30 bis 40 Prozent auf. Die eurasischen Varianten, die ein hämorrhagisches Fieber mit Nierensyndrom (HFRS) verursachen — Puumala, Hantaan, Seoul —, haben eine niedrigere CFR: Puumala 0,1 bis 1 Prozent, Seoul rund 1 bis 2 Prozent, Hantaan 5 bis 15 Prozent. Das Cluster an Bord der MV Hondius betrifft das Andes-Virus, den tödlichsten Stamm. Von den bis zum 7. Mai 2026 gemeldeten acht Fällen sind drei Personen verstorben — eine Letalität von 37,5 Prozent, die mit den historischen Daten zum Andes-Virus übereinstimmt. Eine spezifische antivirale Behandlung gibt es nicht; eine unterstützende intensivmedizinische Versorgung (Sauerstoff, Beatmung, ECMO) gilt als Standardtherapie und verbessert die Prognose bei frühzeitigem Beginn.

No. Mpox is substantially less dangerous than smallpox. Smallpox had a case fatality rate of approximately 30% and caused disfigurement in survivors. Mpox clade II (responsible for the 2022-2024 global outbreak) has a fatality rate below 1% in high-income settings. Mpox clade I, circulating in Central Africa, carries a higher fatality rate of 1-10%, historically higher in children. Smallpox was eradicated globally in 1980; mpox continues to circulate in animal reservoirs and spreads to humans.

The overall case fatality rate (CFR) is approximately 1%, reflecting the high proportion of mild or asymptomatic cases. In hospitalised patients — who represent the severe end of the spectrum — the CFR rises to 15-25%. Lassa fever accounts for an estimated 5,000 deaths per year across West Africa. Pregnant women in the third trimester face especially high risk: foetal mortality approaches 80%, and maternal mortality is also significantly elevated.

Auf Basis der aktuellen Evidenz ist dies nahezu ausgeschlossen. Der WHO-Generaldirektor hat am 7. Mai 2026 öffentlich erklärt, das Cluster der MV Hondius sei 'nicht das nächste COVID'. Drei strukturelle Gründe sprechen dagegen: (1) Das Hantavirus überträgt sich nicht effizient zwischen Menschen — das Andes-Virus, der einzige Stamm mit dokumentierter Mensch-zu-Mensch-Übertragung, erfordert engen, längeren Kontakt, mit einem effektiven R0 in menschlichen Übertragungsketten deutlich unter 1. (2) Das natürliche Reservoir (bestimmte Nagetierarten) ist geografisch begrenzt, sodass eine anhaltende Ausbreitung die Nagetiere und nicht allein erkrankte Menschen voraussetzt. (3) Die hohe Sterblichkeit (30 bis 40 Prozent) verlangsamt die Ausbreitung paradoxerweise, da Wirte sterben oder hospitalisiert werden, bevor sie andere anstecken können — die klassische Dynamik 'zu tödlich, um sich auszubreiten'. Die Polymarket-Wetten bestätigen dies: Die Frage 'Hantavirus-Pandemie 2026' ist nach einem Sprung auf 38 Prozent inzwischen bei 9 Prozent bei einem Volumen von 2,2 Mio. US-Dollar gelandet. Wachsamkeit bleibt angesichts der sechswöchigen Inkubationszeit geboten, eine Pandemie ist jedoch sehr unwahrscheinlich.

The first symptoms of Ebola virus disease appear 2-21 days after exposure (typically 8-10 days) and include abrupt high fever (≥38.6°C/101.5°F), intense headache, severe muscle pain, extreme fatigue, sore throat, and loss of appetite. By days 3-7 a gastrointestinal phase follows, with profuse watery diarrhoea (up to 10 L/day in severe cases), vomiting, abdominal pain, and hiccups. In roughly half of severe cases, a haemorrhagic phase develops around days 5-10 — bleeding from injection sites and mucosal surfaces, and a non-itchy rash on the trunk by day 5-7. A person is not contagious until symptoms begin.

Frühe Symptome von Hantavirus-Infektion und Grippe überschneiden sich: Beide verursachen Fieber, Abgeschlagenheit, Muskelschmerzen und Kopfschmerzen. Klinische Unterlagen der CDC nennen vier Unterscheidungsmerkmale. (1) Beim Hantavirus sind die Muskelschmerzen ausgeprägt und konzentrieren sich auf große Muskelgruppen (Oberschenkel, Hüften, unterer Rücken); bei der Grippe sind die Schmerzen diffuser. (2) Das Hantavirus verursacht zu Beginn selten obere Atemwegssymptome (kein Schnupfen, keine Halsschmerzen); bei der Grippe ist dies häufig der Fall. (3) Beim Hantavirus kommt es 4 bis 10 Tage nach Symptombeginn zu einer raschen respiratorischen Verschlechterung (HPS-Phase) — ein Merkmal, das bei der Grippe nicht auftritt. (4) Das Hantavirus zeigt kein saisonales Muster; die Grippe hat ihren Höhepunkt im Winter. Die CDC betont, dass eine Exposition gegenüber Nagetieren oder Reisen in eine Endemieregion das entscheidende Kriterium ist, das eine Testung auf das Hantavirus auslöst.

Seek emergency care immediately — do not wait — if any of these three warning signs apply: (1) Severe muscle aches (thighs, hips, lower back) with high fever above 38°C (100.4°F), AND a history of rodent contact or rural travel in South America (especially Argentina, Chile, Uruguay) within the past 8 weeks. (2) Progressive shortness of breath or difficulty breathing appearing 4–10 days after a fever begins — this signals the life-threatening cardiopulmonary phase of Hantavirus Pulmonary Syndrome (HPS), which can deteriorate to respiratory failure within hours. (3) Any influenza-like illness if you were a passenger or crew member aboard MV Hondius (2026 Andes virus cluster) within the past 6 weeks — tell the emergency team about your ship itinerary immediately. CDC clinical guidance emphasizes that outcomes improve significantly with early hospitalization, oxygen support, and ICU monitoring before respiratory failure develops. Hantavirus has a 30–40% case fatality rate in HPS — 'it might be the flu' is a dangerous assumption if the exposure risk factors above apply.

Mpox illness typically lasts 2-4 weeks. A prodromal phase of fever, lymphadenopathy, and fatigue precedes the rash by 1-5 days. The rash phase — lesions progressing macule, papule, vesicle, pustule, scab — lasts 2-3 weeks. A person remains infectious from symptom onset until all scabs have fallen off and new skin has healed beneath them. Milder clade IIb cases from the 2022 outbreak (few lesions limited to the genital area) sometimes resolved in under 2 weeks.

Symptoms begin 6-21 days after exposure. Mild cases present with fever, general weakness, headache, sore throat, and mild gastrointestinal symptoms. Severe cases (about 20% of infections) include high fever, chest pain, vomiting, diarrhoea, facial swelling, and haemorrhagic manifestations (bleeding from gums, nose, or eyes). A key late complication is sensorineural hearing loss, occurring in 25-30% of patients — including those who recover from acute illness — and is often permanent.

Measles begins with 3–4 days of high fever (often above 40°C/104°F), cough, runny nose (coryza), and red, watery eyes (conjunctivitis) — known as the '3 Cs'. A key early sign is Koplik's spots: tiny white or grey-blue dots on the inside of the cheeks, appearing 1–2 days before the rash and pathognomonic (unique) to measles. The hallmark maculopapular rash then starts at the hairline and face, spreading downward to the trunk and limbs over 3 days. Fever peaks when the rash appears, then gradually falls if the illness is uncomplicated. Complications include ear infections (about 1 in 10 children), pneumonia (the leading cause of measles deaths), and, rarely, encephalitis (1–2 per 1,000 cases). A lesser-known long-term risk is immune amnesia: measles can wipe out 11–73% of existing antibody memory for 2–3 years, leaving recovered individuals more susceptible to other infections.

Both diseases begin with fever, headache, back pain, and fatigue, followed by a characteristic rash. The key distinguishing features of mpox are: (1) prominent lymphadenopathy (swollen glands) — absent in smallpox; (2) rash lesions may appear in different stages simultaneously; (3) genital/perianal lesions are common in clade IIb. Smallpox lesions were uniform in stage and deeply embedded in the skin. Mpox lesions evolve through macule, papule, vesicle, pustule, scab, typically over 2-4 weeks. In the 2022 clade IIb outbreak, many cases presented with few lesions limited to the genital area without a classical widespread rash.

Eine Hantavirus-Infektion verläuft typischerweise in zwei Phasen (CDC). Die frühe fieberhafte Phase dauert 1 bis 7 Tage und umfasst Fieber, starke Muskelschmerzen (Oberschenkel, Hüften, Rücken, Schultern), Abgeschlagenheit, Kopfschmerzen, Schwindel, Schüttelfrost sowie gelegentlich Übelkeit, Erbrechen oder Bauchschmerzen. Die spätere kardiopulmonale Phase, 4 bis 10 Tage nach Symptombeginn bei HPS-Fällen (Andes, Sin Nombre), äußert sich in Husten, Atemnot, Flüssigkeitsansammlung in der Lunge und rasch fortschreitendem Atemversagen. HFRS-Varianten (Puumala, Hantaan, Seoul) verursachen zusätzlich akutes Nierenversagen und Blutungserscheinungen. Klinisch unterscheidet sich das Hantavirus von Influenza oder COVID-19 vor allem durch den abrupten Übergang in eine schwere respiratorische Verschlechterung in HPS-Fällen.

Yes. China reports the world's highest annual burden of hantavirus disease, with roughly 10,000 to 20,000 cases of hemorrhagic fever with renal syndrome (HFRS) each year — mostly caused by Hantaan virus and Seoul virus carried by Apodemus agrarius (striped field mouse) and Rattus norvegicus (brown rat) respectively. Provinces with the highest incidence are Shaanxi, Heilongjiang, Shandong, and Liaoning. The 2025 epidemiological report from China CDC showed continued decline from 1980s peaks (which exceeded 100,000 cases per year) thanks to rodent control programs and the domestic inactivated bivalent vaccine Hantavax (Hantaan + Seoul, licensed in China since 1994). The MV Hondius 2026 outbreak involves Andes virus — a New World strain unrelated to Chinese-endemic strains — and is therefore epidemiologically separate from China's ongoing HFRS background activity. Travelers to China face very low hantavirus risk in urban areas; rural cabins and grain storage with active rodent infestation are the historical exposure setting.

No. Hantavirus is not an identified health risk for Hajj or Umrah pilgrims. Saudi Arabia's Arabian Peninsula geography does not support endemic hantavirus circulation: no rodent species carrying pathogenic hantavirus strains (such as Andes virus, Sin Nombre virus, or Puumala virus) are established in the region. WHO's Eastern Mediterranean Regional Office (EMRO) does not list hantavirus among zoonotic disease priorities for Saudi Arabia or neighboring Gulf states. The MV Hondius 2026 cluster does not involve any Saudi Arabian, Gulf, or Levantine passengers among confirmed cases or priority contact-tracing lists as of May 2026. For Hajj health priorities, WHO and the Saudi Ministry of Health focus on meningococcal meningitis (ACWY vaccine mandatory for many nationalities), MERS-CoV (Middle East Respiratory Syndrome), respiratory infections, heat illness, and food safety. No hantavirus-specific measures are required or recommended for travel to Saudi Arabia or any other country in the Middle East and North Africa region.

Travel to South America remains safe for most itineraries, but travelers should understand the geographically specific risk from Andes virus. Risk zones are rural areas — particularly Patagonia and the Four Corners region of Argentina (Neuquén, Río Negro, Chubut, Santa Cruz provinces), southern Chile (Regions X–XIV), and parts of Uruguay — not major cities such as Buenos Aires, Santiago, or Montevideo. WHO has not issued a travel advisory against South America for hantavirus. The 2026 MV Hondius cluster arose from a single index case who spent four months in these rural endemic areas. Recommended precautions: avoid sleeping or spending extended time in rodent-infested rural huts, barns, or storage buildings; if camping, use elevated sleeping platforms away from field mouse habitat; never sweep rodent droppings in enclosed spaces — wet them first with 1:10 bleach solution before cleaning. Travelers developing fever, intense muscle pain, and respiratory difficulty within 8 weeks of returning from rural endemic areas in Argentina or Chile should disclose that travel history to emergency physicians immediately.

Hantavirus risk follows rodent population cycles, which vary by region and species. United States (Sin Nombre virus): cases peak in late spring and early summer (May–July) in the US Southwest, correlating with the deer mouse (Peromyscus maniculatus) breeding season that drives rodents into human structures — cabins, barns, and outbuildings closed over winter. The CDC notes that 'spring cleaning' of rural cabins without proper precautions (sweeping dry droppings without a mask) is a recurring documented exposure scenario. Scandinavia and Northern Europe (Puumala virus): cases spike in autumn and winter when bank voles (Myodes glareolus) move into homes and farm buildings. Outbreak years correlate with vole population boom cycles every 3–4 years. South America (Andes virus): year-round transmission with no sharply defined peak; cases rise slightly in autumn and winter in Argentina and Chile when cooler temperatures push rodents indoors. The MV Hondius index case was exposed between November 2025 and April 2026 — an autumn-to-early-autumn window in the Southern Hemisphere. Traveler advice: high-risk activities in endemic regions (wilderness camping, cleaning rural structures) carry elevated risk during local rodent breeding seasons. Check CDC country-specific travel advisories before visiting endemic areas.

Hantavirus-Spezies sind weltweit verbreitet, mit regionalen Schwerpunkten. Amerika: Sin-Nombre-Virus (Four-Corners-Region der USA — New Mexico, Arizona, Colorado, Utah — sowie Kalifornien, Oregon, Washington), Andes-Virus (Argentinien, Chile, Uruguay), Bayou- und Black-Creek-Canal-Virus (US-Golfstaaten), Choclo-Virus (Panama). Europa: Puumala-Virus (Skandinavien, Baltikum, Russland, Deutschland, Frankreich, Belgien, begrenzt in Norditalien), Dobrava-Belgrad-Virus (Balkan). Asien: Hantaan-Virus (China, Korea), Seoul-Virus (weltweit über Wanderratten), Amur-Virus (östliches Russland). Afrika: Sangassou-Virus (Guinea — bislang nur begrenzt humanmedizinisch bekannt). Der Ausbruch auf der MV Hondius betrifft das Andes-Virus aus Südamerika. Das Schiff befindet sich derzeit vor Kap Verde (Westafrika, ohne endemisches Hantavirus) auf dem Weg zu den Kanarischen Inseln (Spanien).

There is no documented endemic hantavirus circulation in the Arabian Peninsula (Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, Oman, Yemen) or in the Levant (Jordan, Lebanon, Syria, Iraq, Palestine, Israel). Limited serological surveys in Egypt and Turkey have detected hantavirus antibodies in commensal rodents (likely Seoul virus from Rattus norvegicus), but no clinically significant human cases linked to those reservoirs have been reported. The WHO Eastern Mediterranean Regional Office (EMRO) does not list hantavirus among priority emerging zoonoses for the region. The MV Hondius 2026 outbreak does not currently involve any Middle Eastern country in confirmed-case or contact-tracing lists. Risk to residents and travelers within the region remains very low, including for pilgrims attending Hajj or Umrah in Saudi Arabia, where the primary health concerns remain meningococcal disease, MERS-CoV, respiratory infections, and heat illness.

Italien verzeichnet keine dokumentierten autochthonen (lokal erworbenen) Fälle einer Hantavirus-Erkrankung. Das Puumala-Virus (PUUV) — eine mildere Hantavirus-Spezies, die HFRS verursacht — ist in einigen nördlichen Alpenregionen (Trentino-Südtirol, Friaul-Julisch Venetien) begrenzt vorhanden, jedoch ohne neuere humane Fälle. Das ECDC stuft das Risiko für die allgemeine europäische Bevölkerung durch den Ausbruch der MV Hondius als 'sehr gering' ein. Das italienische Gesundheitsministerium hat die Überwachung von Reiserückkehrern aus Südamerika während des relevanten Expositionszeitraums dennoch verstärkt.

Yes — measles is back in the United States and in several other countries in 2026. The US is experiencing its largest measles resurgence in decades: over 2,104 confirmed cases were reported to the CDC by mid-2026, surpassing every annual total since before the disease was declared eliminated in 2000. The outbreak is driven entirely by communities with low two-dose MMR vaccination coverage, not by a change in the virus itself. The measles virus (Measles morbillivirus) is genetically unchanged and the MMR vaccine remains highly effective (97% with two doses). States most affected include Texas, Montana, and others where pockets of unvaccinated individuals allowed the virus to sustain chains of transmission. Globally, WHO reports active outbreaks in Romania, Italy, the Democratic Republic of Congo, and several countries in sub-Saharan Africa and Southeast Asia in 2025–2026. Measles is not 'back' as an endemic pathogen in the USA — elimination status is maintained as long as no continuous year-round chain of domestic transmission is established — but the current outbreak is a serious public-health warning about the consequences of falling vaccination rates.

Nigeria has the highest reported burden, with thousands of cases annually tracked by the Nigeria Centre for Disease Control (NCDC). Sierra Leone, Liberia, and Guinea are also highly endemic. Sporadic cases have occurred in Mali, Ivory Coast, and Benin. International importation has been recorded in Europe and North America among returning travellers. The WHO regularly issues Disease Outbreak News alerts for Nigeria, with peak transmission typically between January and April.

Yes. The United States is experiencing a significant measles resurgence in 2025–2026, with case counts reaching levels not seen since 2019. Outbreaks have been concentrated in communities with low MMR vaccination rates — particularly among unvaccinated children and adults in states including Texas, Montana, and others. Measles was declared eliminated from the USA in 2000, meaning there is no longer sustained year-round transmission; however, outbreaks still occur when unvaccinated travelers import the virus and it spreads through under-immunized pockets of the population. The CDC monitors all cases and recommends two-dose MMR vaccination as the primary prevention measure. International travel to countries with active measles transmission increases exposure risk for unvaccinated individuals. Parents should confirm their children have received two MMR doses on schedule; adults who are unsure of their vaccination history should consult a physician.

The MV Hondius hantavirus cluster (Andes virus, 2026) spans multiple countries across four continents. Countries with confirmed or suspected patients receiving treatment: Netherlands (two confirmed deaths; ship is Dutch-flagged), Germany (patient transferred by medical evacuation), Switzerland (patient hospitalized), South Africa (patient transferred by medical evacuation), and Saint Helena (30 passengers disembarked 24 April 2026). Countries with active contact-tracing operations for passengers or crew who traveled onward: United States (17 American nationals were aboard), United Kingdom, France, Spain (final port call scheduled Las Palmas, Canary Islands, approximately 11 May 2026), Canada, Singapore. Countries involved in the index case's pre-embarkation travel (Andes virus exposure corridor): Argentina (Ushuaia departure port; index case traveled through southern Argentina for four months), Chile, Uruguay. WHO Disease Outbreak News DON599 covers 23 nationalities aboard. ECDC rates the risk to EU/EEA general public as 'very low'.

Hantavirus is diagnosed using a combination of laboratory tests and clinical criteria. The gold standard for Hantavirus Pulmonary Syndrome (HPS) is serology: IgM and IgG ELISA antibody tests that become positive within days of symptom onset. RT-PCR (reverse-transcription polymerase chain reaction) can detect viral RNA in blood during the early febrile phase before antibodies develop, and was used to confirm Andes virus in the MV Hondius cluster cases. Supportive CBC findings include thrombocytopenia (platelets often below 150,000/µL), immunoblasts (activated lymphocytes), hemoconcentration (rising hematocrit), and left-shifted neutrophilia. Chest X-ray and CT show bilateral interstitial infiltrates as HPS progresses to pulmonary edema. Diagnosis typically combines a compatible clinical picture, recent rodent exposure or travel to an endemic area, and confirmatory serology or PCR. Standard influenza or COVID-19 tests will NOT detect hantavirus — physicians must order specific hantavirus serology panels, available through most state and national reference laboratories in the US, EU, Argentina, and Chile.

The MV Hondius 2026 Andes hantavirus outbreak unfolded over six months across four continents. November 2025–April 2026: Patient Zero travels overland for four months through Argentina, Chile, and Uruguay — the endemic zone for Andes virus — before boarding. April 1, 2026: MV Hondius departs Ushuaia, Argentina with 197 passengers and crew from 23 nationalities. April 6: First passenger develops symptoms; hantavirus not yet suspected. April 11: First fatality — a Dutch passenger dies five days after symptom onset; hantavirus identified retroactively from preserved samples. April 24: 30 passengers disembark at Saint Helena (remote South Atlantic island), triggering a global contact tracing operation across six additional countries. May 4: WHO opens Disease Outbreak News DON599 — the first international alert — confirming a multi-country hantavirus cluster. May 5: Polymarket's 'Hantavirus pandemic 2026' market peaks at 38% probability, with $1.3 million in trading volume. May 7: WHO Director-General states the outbreak is 'not the next COVID'; 5 confirmed cases, 2 deaths confirmed; 2,500 diagnostic kits dispatched to five countries. May 11: MV Hondius arrives Las Palmas de Gran Canaria (Canary Islands, Spain) for final disembarkation of remaining 146 passengers. June 2026: Active contact tracing continues in multiple countries within the 8-week incubation window; total confirmed deaths: 3.

The MV Hondius cluster is the active hantavirus outbreak as of 2026. Live counts (confirmed cases, suspected cases, deaths, affected countries, and people under contact tracing) are shown on the homepage KPI bar and refresh hourly from D1. Patients are hospitalized in the Netherlands, Germany, Switzerland, South Africa, and Saint Helena; contact tracing remains active in the United States, Singapore, Canada, France, the United Kingdom, and Spain. WHO, CDC, ECDC, PAHO, and Africa CDC have each issued situational updates. Prediction markets on Polymarket are tracking the probability of WHO declaring a pandemic in 2026 and additional country-specific case confirmations — see the Markets section for live odds. All numbers update hourly from 50+ sources; this FAQ deliberately avoids hardcoded figures so it never goes stale.

Mit Stand 7. Mai 2026 verzeichnet das Cluster der MV Hondius acht gemeldete Fälle (fünf laborbestätigt, drei Verdachtsfälle vor der Bestätigung) und drei Todesfälle. Die Fälle verteilen sich auf fünf Länder, in denen Patientinnen und Patienten stationär behandelt werden: Niederlande, Deutschland, Schweiz, Südafrika und Sankt Helena. Kontaktnachverfolgung läuft aktiv in mindestens sechs weiteren Ländern: USA, Singapur, Kanada, Frankreich, Vereinigtes Königreich und Spanien. Über das Hondius-Cluster hinaus treten in Endemieregionen jährlich sporadische Hantavirus-Fälle auf: typischerweise 20 bis 40 Fälle pro Jahr in den USA (Sin Nombre), 100 bis 200 in Argentinien (Andes) und mehrere tausend HFRS-Fälle in ganz Eurasien (Puumala, Hantaan, Seoul). Der aktuelle Ausbruch ist nicht wegen der Fallzahl ungewöhnlich, sondern wegen seiner länderübergreifenden Ausbreitung durch eine Kreuzfahrtreise.

No. Mpox is not eradicated. Smallpox is the only human disease ever declared eradicated (WHO, 1980), achieved through a global vaccination campaign. Mpox continues to circulate in animal reservoirs (primarily rodents in Central and West Africa) and causes recurrent human outbreaks. The 2022-2024 global mpox outbreak (clade IIb) led the WHO to declare a Public Health Emergency of International Concern (PHEIC) twice: in 2022 and again in August 2024 when clade I expanded in the DRC and neighbouring countries. Eradication of mpox is not currently feasible given its animal reservoir.

Das Andes-Virus (ANDV) ist eine Hantavirus-Spezies, die im südlichen Südamerika endemisch ist, insbesondere in Argentinien, Chile sowie Teilen Uruguays und Boliviens. Es ist nach dem Gebirgszug der Anden benannt, in dem die langschwänzige Zwergreisratte (Oligoryzomys longicaudatus) — ihr wichtigstes natürliches Reservoir — weit verbreitet ist. Das ANDV verursacht das Hantavirus-Lungensyndrom (HPS) mit einer Letalität von 30 bis 40 Prozent und ist unter den Hantaviren einzigartig in seiner Fähigkeit zur begrenzten Mensch-zu-Mensch-Übertragung, die in Clustern bis zum Ausbruch in El Bolsón (Argentinien) 1996 belegt ist. Das Cluster der MV Hondius betrifft das Andes-Virus; der Indexpatient ist zwischen November 2025 und April 2026 ausgiebig durch Argentinien, Chile und Uruguay gereist.

Ebola virus disease (EVD) is a severe, often fatal illness caused by viruses of the Ebolavirus genus (family Filoviridae). Six species are known — Zaire, Sudan, Bundibugyo, Taï Forest, Reston, and Bombali ebolavirus — with case-fatality rates historically ranging 25-90% depending on strain and access to care. The natural reservoir is believed to be fruit bats (Pteropodidae); spillover to humans occurs via contact with infected wildlife, then spreads human-to-human through direct contact with blood or body fluids. The active 2026 outbreak in the Democratic Republic of the Congo and Uganda, declared a WHO Public Health Emergency of International Concern on 18 May 2026, is caused by Bundibugyo ebolavirus, for which no vaccine or monoclonal antibody therapy is currently approved.

Hantavirus is a family of RNA viruses (family Hantaviridae) transmitted primarily from rodents to humans. Depending on the species, it causes two distinct syndromes: Hantavirus Pulmonary Syndrome (HPS), marked by severe respiratory failure and 30–40% mortality in the Americas (Andes, Sin Nombre viruses), and Hemorrhagic Fever with Renal Syndrome (HFRS), affecting the kidneys in Eurasia (Hantaan, Puumala, Seoul viruses) with 1–15% mortality. There is no specific antiviral treatment or internationally approved vaccine. Infection occurs mainly through inhalation of aerosolized rodent excreta (urine, droppings, saliva). In 2026, the primary active cluster involves the Andes virus, linked to the MV Hondius cruise ship.

Lassa fever is an acute viral haemorrhagic illness caused by Lassa mammarenavirus (Arenaviridae family). It is endemic in West Africa — primarily Nigeria, Sierra Leone, Liberia, and Guinea — and was first identified in 1969 in Lassa, Nigeria. The disease is a zoonosis: its primary reservoir is the multimammate rat (Mastomys natalensis). Approximately 80% of infections are mild or asymptomatic; the remaining 20% can progress to severe disease involving haemorrhagic manifestations and multi-organ failure.

Mit Stand 7. Mai 2026 liegt die MV Hondius in den Hoheitsgewässern vor Kap Verde; die WHO und ein an Bord entsandter medizinischer Sachverständiger leiten die Lagebeurteilung an Bord. Das Schiff soll um den 11. Mai 2026 Las Palmas auf den Kanarischen Inseln (Spanien) erreichen, wo die endgültige Ausschiffung und das medizinische Screening der verbliebenen 146 Passagiere aus 23 Ländern erfolgen. Frühere Ausschiffungen umfassten 30 Passagiere in Sankt Helena am 24. April sowie einzelne medizinische Evakuierungen nach Südafrika, in die Niederlande, nach Deutschland und in die Schweiz. Das Schiff hat Ushuaia in Argentinien am 1. April 2026 verlassen.

Isolation requirements differ by hantavirus species. For most variants (Sin Nombre, Puumala, Hantaan, Seoul): standard contact precautions are sufficient because there is no documented human-to-human transmission. Healthcare workers should use standard PPE (gloves, surgical mask, eye protection) during procedures that generate aerosols from bodily fluids. For Andes virus — the strain in the MV Hondius 2026 cluster — WHO and ECDC recommend upgraded droplet-plus-contact precautions given the documented, albeit rare, human-to-human transmission risk. This means N95 or equivalent respirator, gown, gloves, and eye shield for direct patient care. The CDC advises airborne precautions (negative-pressure room + N95) when performing high-aerosol procedures such as intubation or bronchoscopy on suspected HPS patients. In the MV Hondius outbreak, WHO distributed 2,500 diagnostic kits and issued specific healthcare-worker guidance emphasizing that Andes virus requires a heightened precautionary approach. Household contacts of Andes virus patients should self-monitor for symptoms for 8 weeks from last exposure; they do not require medical isolation unless symptomatic.

Die Präventionsempfehlungen der CDC konzentrieren sich darauf, den Kontakt zu Nagetieren möglichst gering zu halten. Die Standardempfehlungen lauten: (1) Öffnungen über einem Viertel Zoll an Häusern, Schuppen und Hütten verschließen, damit Nagetiere keinen Zugang finden. (2) Nagetiere mit Schlagfallen in betroffenen Bereichen fangen; nicht ausschließlich mit Gift arbeiten (Kadaver müssen weiterhin sicher entsorgt werden). (3) Vor Betreten lange geschlossener Räume (Hütten, Garagen, Lagerschuppen) Türen und Fenster mindestens 30 Minuten zur Lüftung öffnen. (4) Staub und Ausscheidungen vor der Reinigung mit einer Bleichlauge (1:10) anfeuchten; trockene Nagetierausscheidungen niemals fegen oder saugen, da hierbei Viruspartikel aerosolisiert werden. (5) Beim Umgang mit möglicher Nagetierkontamination Gummi- oder Latexhandschuhe und eine FFP2-/N95-Maske tragen. (6) Lebensmittel in nagetiersicheren Behältern aufbewahren. Reisende in Endemieregionen sollten es vermeiden, in mit Nagetieren befallenen Hütten oder Zelten zu übernachten.

Prevention focuses on reducing contact with the multimammate rat (Mastomys natalensis), the primary animal reservoir. Key measures recommended by the WHO and CDC include: (1) Store food in rodent-proof containers and dispose of garbage away from the home. (2) Keep homes clean and seal entry points to discourage rats. (3) Avoid contact with rodents, their nests, urine, or faeces. (4) Healthcare workers must use appropriate personal protective equipment (PPE) — gloves, gowns, masks — when caring for suspected or confirmed Lassa fever patients, and follow strict infection control protocols. (5) Community education in endemic areas (Nigeria, Sierra Leone, Liberia, Guinea) on the risks of handling or consuming rats. There is currently no approved vaccine for Lassa fever, though multiple candidates are in clinical development under CEPI funding.

The MMR (measles-mumps-rubella) vaccine is highly effective. A single dose provides approximately 93% protection against measles; two doses provide approximately 97% protection. The two-dose schedule — first at 12–15 months, second at 4–6 years — is the global standard recommended by WHO and CDC and is why measles was declared eliminated from the USA in 2000. Protection from two doses is generally lifelong for the vast majority of vaccinated people. Adults born before 1957 are presumed immune from prior natural infection. Adults born in 1957 or later who haven't had measles or received two vaccine doses should get vaccinated. The 2025–2026 USA resurgence is driven entirely by communities with low two-dose MMR coverage — not by the vaccine failing, but by vaccination gaps allowing the virus to find susceptible hosts.

WHO and ECDC issued specific guidance for the approximately 197 passengers and crew aboard MV Hondius following the Andes hantavirus cluster. Recommended actions: (1) Self-monitor daily for fever (>38°C / 100.4°F), severe muscle aches in the thighs, hips, or back, fatigue, or any breathing difficulty for 8 weeks from last potential exposure aboard the ship. (2) If symptoms develop, call emergency services immediately and inform them of your travel on MV Hondius — do not self-drive to an emergency room. Provide the ship's name, dates aboard, and cabin number to the receiving healthcare team. (3) Passengers who disembarked at Saint Helena on 24 April 2026 should have already been contacted by local health authorities; if not, contact your national health authority directly. (4) Normal daily activities including work may continue while asymptomatic — Andes virus is NOT spread through casual contact, shared office air, or public transport. (5) Defer blood donation until 8 weeks after disembarkation. WHO distributed diagnostic kits to all countries known to host former passengers or crew, covering 23 nationalities. Your national traveler health hotline can provide country-specific guidance.

Yes. Smallpox vaccines provide cross-protection against mpox because both viruses are orthopoxviruses. The JYNNEOS vaccine (MVA-BN, Imvamune/Imvanex) is specifically approved for both mpox and smallpox prevention. ACAM2000 (the replication-competent vaccinia vaccine) is also protective but carries more side-effect risks. Pre-1980 smallpox vaccination campaigns conferred approximately 85% protection against mpox; that immunity has waned in the global population since routine vaccination stopped. JYNNEOS is now recommended as a 2-dose series for at-risk individuals in many countries.

Survivors of Hantavirus Pulmonary Syndrome (HPS) can make full recoveries, but the critical window is narrow. Once the cardiopulmonary phase begins — typically 4–10 days after symptom onset — patients may deteriorate rapidly from mild dyspnea to full respiratory failure within hours. Early ICU admission with supplemental oxygen, mechanical ventilation, and in severe cases ECMO (extracorporeal membrane oxygenation, heart-lung bypass) is the standard of care and significantly improves survival odds. Most survivors who receive adequate ICU support are discharged within 2–6 weeks. Long-term sequelae: some HPS survivors experience reduced pulmonary function for several months but most regain normal lung capacity within a year. There is no known chronic carrier state for hantavirus — the virus does not persist indefinitely after recovery. Hemorrhagic Fever with Renal Syndrome (HFRS) variants (Puumala, Hantaan) have a better prognosis overall (case fatality 0.1–15%) and renal function typically recovers, though dialysis may be needed acutely. The three deaths in the MV Hondius 2026 cluster occurred before ECMO could be initiated, underscoring that rapid recognition and early ICU transfer are the main modifiable survival factors.

Mit Stand Mai 2026 ist kein Hantavirus-Impfstoff durch WHO, FDA oder EMA zugelassen. Südkorea und China setzen national inaktivierte Hantavirus-Impfstoffe (z. B. Hantavax) gegen HFRS-Stämme (Hantaan, Seoul) ein; diese sind international nicht zugelassen und schützen nicht vor den HPS-Stämmen der Neuen Welt (Andes, Sin Nombre). Mehrere Impfstoffkandidaten gegen Andes- und Sin-Nombre-Virus befinden sich in der frühen Forschung und in Phase-1-Studien, eine Zulassung wird jedoch nicht vor 2028 erwartet. Die Polymarket-Frage 'Hantavirus-Impfstoff 2026 zugelassen?' wird derzeit mit einer Wahrscheinlichkeit von 2 Prozent gehandelt.

For Zaire ebolavirus, yes: Ervebo (rVSV-ZEBOV-GP, Merck) has been FDA/EMA-approved since 2019 and is used in ring vaccination during outbreak response, and two monoclonal antibody therapies — Ebanga (mAb114) and Inmazeb (REGN-EB3) — are FDA-approved and reduce mortality when given early. Sudan ebolavirus vaccine candidates are in advanced trials but not yet WHO-prequalified. Critically, the active 2026 outbreak in the DRC and Uganda is caused by Bundibugyo ebolavirus, for which no vaccine or monoclonal antibody therapy is currently approved — treatment there relies on supportive intensive care (fluids, electrolyte balance, oxygen, blood pressure support).

Ribavirin, an antiviral drug, is effective when given early — ideally within 6 days of fever onset. Early supportive care (IV fluids, electrolyte correction, treating secondary infections) also significantly improves outcomes. Convalescent plasma has been explored but its efficacy is not firmly established. There is currently no WHO-approved vaccine for Lassa fever, though multiple vaccine candidates are in clinical development.

There is no approved specific antiviral drug for measles. Treatment is supportive — meaning it aims to reduce symptoms and prevent complications rather than directly kill the virus. Key elements include: adequate hydration, fever management with acetaminophen or ibuprofen (never aspirin in children), and vitamin A supplementation — WHO recommends two high-dose vitamin A doses for all children with measles, as it has been shown to significantly reduce measles mortality and the severity of complications including blindness and pneumonia. Secondary bacterial infections (the most common cause of measles-related deaths in both children and adults) are treated with appropriate antibiotics. Severe pneumonia and measles encephalitis require hospitalization and may need intensive care. The best 'treatment' remains prevention: two doses of MMR vaccine before exposure provide lifelong protection in ~97% of recipients.

Tecovirimat (TPOXX/ST-246) is an antiviral approved by the FDA and EMA specifically for the treatment of orthopoxvirus infections including mpox. Brincidofovir and cidofovir are alternative antivirals used in severe cases. For most people with clade II mpox, illness is self-limiting and resolves within 2-4 weeks with supportive care (pain management, wound care, hydration). Severe cases — clade I infection, immunocompromised patients, children, or extensive skin involvement — require antiviral treatment and may need hospitalisation.

Die beiden Viren unterscheiden sich in nahezu allen epidemiologisch relevanten Dimensionen. Übertragung: COVID-19 (SARS-CoV-2) verbreitet sich effizient zwischen Menschen über Tröpfchen und Aerosole; das Hantavirus ist überwiegend zoonotisch (Nagetier auf Mensch), wobei nur das Andes-Virus selten eine begrenzte Mensch-zu-Mensch-Übertragung bei engem, längerem Kontakt zeigt. Basisreproduktionszahl R0: COVID-19 ursprünglich 2 bis 3, aktuelle Varianten bis zu 8 bis 15; das Andes-Virus liegt in der Mensch-zu-Mensch-Übertragung bei unter 1, sodass anhaltende Ausbrüche unwahrscheinlich sind. Sterblichkeit: COVID-19 bevölkerungsweit 0,5 bis 2 Prozent; Andes-Hantavirus 30 bis 40 Prozent. Pandemisches Potenzial: COVID-19 hat weltweit Millionen Todesfälle verursacht; das Hantavirus hat nie eine Pandemie ausgelöst, und die WHO stuft das aktuelle Risiko als gering ein. Das Cluster an Bord der MV Hondius mit acht Fällen zum 7. Mai 2026 ist ein eingegrenztes zoonotisches Ereignis und nicht der Beginn einer Pandemie.

Hantavirus vs Ebola — Sterblichkeit 30-40 % vs 25-90 %, Reservoir Nagetiere vs Flughunde, kein Impfstoff vs Ervebo. 7 Schlüsselunterschiede und Live-Fallzahlen 2026. (1) Reservoir: Hantavirus in Nagetieren (Hirschmäuse, Rötelmäuse); Ebola in Flughunden und nicht-menschlichen Primaten. (2) Mensch-zu-Mensch-Übertragung: Hantavirus selten (nur Andes-Stamm, enger längerer Kontakt); Ebola ja, effizient über Körperflüssigkeiten, bis hin zu Ausbrüchen mit Tausenden Fällen. (3) Sterblichkeit: Hantavirus-Lungensyndrom (HPS) 30-40 % (Andes-Virus); Ebola 25-90 % je nach Stamm — Ebola-Zaire historisch 50-90 %. (4) Impfstoff: Hantavirus keiner international zugelassen; Ebola hat Ervebo (rVSV-ZEBOV), seit 2019 von FDA und EMA für Ebola-Zaire zugelassen, plus fortgeschrittene Kandidaten für Ebola-Sudan. (5) Behandlung: beide erfordern unterstützende Intensivpflege; Ebola hat zusätzlich zwei FDA-zugelassene monoklonale Antikörpertherapien — Inmazeb (REGN-EB3) und Ebanga (mAb114), die die Sterblichkeit bei früher Gabe drastisch senken. (6) Wichtige Ausbrüche: Hantavirus Argentinien 1996, USA 1993 (Four Corners) und der aktuell verfolgte MV-Hondius-Cluster 2026. Ebola Westafrika 2014-2016 (28.600 Fälle / 11.300 Todesfälle), DRK 2018-2020 (3.470 Fälle / 2.287 Todesfälle), plus wiederkehrende Ausbrüche in Uganda. (7) Pandemiepotenzial: beide blieben historisch regional; keiner erreichte je globale Pandemie-Stufe. Verfolge beide live: MV-Hondius-Cluster auf outbreakwatch.net und Ebola Situation Watch 2026 auf outbreakwatch.net/ebola.

Both are African viral haemorrhagic fevers, but they differ significantly. Lassa is caused by an arenavirus, Ebola by a filovirus. Lassa is endemic and causes tens of thousands of cases annually; Ebola causes sporadic large outbreaks. Lassa's overall CFR (~1%) is much lower than Ebola's (25-90%), though hospitalised Lassa patients face higher mortality (~15-25%). Lassa does not spread person-to-person as easily as Ebola. Both require similar PPE for healthcare workers.

Mpox and smallpox are both caused by orthopoxviruses, but they are distinct diseases. Smallpox (Variola virus) was eradicated in 1980 and no longer occurs naturally. Mpox (Monkeypox virus) is an ongoing zoonotic disease, with outbreaks in 2022-2024 (clade IIb, global) and 2024-2025 (clade I, primarily Democratic Republic of Congo). Key clinical difference: mpox causes prominent lymphadenopathy (swollen lymph nodes), which does NOT occur in smallpox. Mpox is significantly less severe: clade II fatality rate is under 1%, while smallpox killed approximately 30% of those infected.

Prognosemärkte sind bei Ereignissen mit ausreichendem Handelsvolumen und öffentlicher Datenlage relativ gut kalibriert, weisen aber bei neuartigen Krankheitsausbrüchen bekannte Schwächen auf. Stärken: Sie bündeln unterschiedliche Perspektiven und passen sich rasch an neue Daten an. Grenzen bei Ausbrüchen: (1) Geringe Liquidität in frühen Ausbruchsmärkten — wenige Händler können die Preise erheblich bewegen. (2) Resolution-Risiko — was als 'offizielle Pandemieerklärung' gilt, kann selbst umstritten sein. (3) Informationsasymmetrie — Gesundheitsbehörden verfügen über nicht öffentliche Daten. (4) Reflexivität — sobald Märkte selbst zur Nachricht werden, können sie das beeinflussen, was sie vorhersagen sollen. Der Polymarket-Markt 'Hantavirus-Pandemie 2026' überschreitet derzeit 3,5 Mio. US-Dollar Volumen: ausreichend Liquidität, um einer Manipulation durch Einzelne standzuhalten, gleichwohl volatil und empfindlich gegenüber Aussagen der WHO.

Ein Prognosemarkt ist ein Online-Marktplatz, auf dem Teilnehmerinnen und Teilnehmer Anteile kaufen und verkaufen, deren Wert vom Ausgang eines künftigen Ereignisses abhängt. Bei Ja/Nein-Ereignissen zahlt ein JA-Anteil 1 US-Dollar aus, wenn das Ereignis eintritt, und 0 US-Dollar andernfalls; der aktuelle Kurs zwischen 0 und 1 US-Dollar entspricht der vom Markt aggregierten Wahrscheinlichkeit. Werden 'Hantavirus-Pandemie 2026?'-JA-Anteile beispielsweise zu 0,09 US-Dollar gehandelt, liegt die geschätzte Wahrscheinlichkeit bei 9 Prozent. Zu den wichtigsten Prognosemärkten zählen Polymarket (auf Kryptobasis, global) und Kalshi (regulierte US-Derivatebörse). Sie werden in der Forschung häufig als Prognosesignal für Ereignisse von Wahlen bis zu Krankheitsausbrüchen genutzt, da die Aggregation vieler Händlerwetten kalibrierte Wahrscheinlichkeiten liefern kann. OutbreakWatch zeigt Daten von Polymarket und Kalshi an; wir ermöglichen keinen Handel.

Der Polymarket-Markt 'Hantavirus-Pandemie 2026?' war einer der volatilsten Gesundheitsmärkte des Jahres. Er wurde am 4. Mai 2026 mit 3,5 Prozent eröffnet, stieg am 5. Mai auf 38 Prozent, als erste Meldungen über Mensch-zu-Mensch-Übertragungen und Todesfälle eintrafen, und fiel bis zum 7. Mai wieder auf 9 Prozent zurück, nachdem der WHO-Generaldirektor das Cluster öffentlich als 'nicht das nächste COVID' eingeordnet hatte. Das gesamte Handelsvolumen hat 2,2 Mio. US-Dollar überschritten. Die Bewegungen spiegeln eine Echtzeit-Einschätzung des Schwarms zu drei Signalen wider: (1) die Risikoeinschätzung der WHO, (2) neue Fallmeldungen außerhalb des ursprünglichen Schiffsclusters und (3) die sechswöchige Inkubationszeit, durch die bis Mitte Juni 2026 weitere Fälle auftreten können. Der Markt wird am 31. Dezember 2026 aufgelöst — die Wettenden preisen die gesamte Tail-Risiko-Spanne von acht Monaten ein.